BR112015016447A8 - fragmentos de anticorpos, composições e usos dos mesmos - Google Patents

fragmentos de anticorpos, composições e usos dos mesmos

Info

Publication number
BR112015016447A8
BR112015016447A8 BR112015016447A BR112015016447A BR112015016447A8 BR 112015016447 A8 BR112015016447 A8 BR 112015016447A8 BR 112015016447 A BR112015016447 A BR 112015016447A BR 112015016447 A BR112015016447 A BR 112015016447A BR 112015016447 A8 BR112015016447 A8 BR 112015016447A8
Authority
BR
Brazil
Prior art keywords
constant domains
chain constant
compositions
antibody fragments
polypeptide
Prior art date
Application number
BR112015016447A
Other languages
English (en)
Inventor
Vigna Elisa
Maria Comoglio Paolo
Michieli Paolo
Original Assignee
Metheresis Translational Res S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Res S A filed Critical Metheresis Translational Res S A
Publication of BR112015016447A8 publication Critical patent/BR112015016447A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1/1 resumo “novos fragmentos de anticorpos, composições e usos dos mesmos” fragmento de anticorpo compreendendo um primeiro polipeptídeo compreendendo um domínio variável e dois domínios constantes de cadeia leve e um segundo polipeptídeo compreendendo um domínio variável e dois domínios constantes de cadeia pesada, em que dois domínios constantes de cadeia são domínios constantes de cadeia leve e dois domínios constantes são domínios constantes de cadeia pesada ch1.
BR112015016447A 2013-01-09 2014-01-07 fragmentos de anticorpos, composições e usos dos mesmos BR112015016447A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000012A ITTO20130012A1 (it) 2013-01-09 2013-01-09 Nuovi frammenti anticorpali, relative composizioni ed usi
PCT/IB2014/058098 WO2014108829A1 (en) 2013-01-09 2014-01-07 New antibody fragments, compositions and uses thereof

Publications (1)

Publication Number Publication Date
BR112015016447A8 true BR112015016447A8 (pt) 2018-01-23

Family

ID=47790367

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015016447A BR112015016447A8 (pt) 2013-01-09 2014-01-07 fragmentos de anticorpos, composições e usos dos mesmos

Country Status (28)

Country Link
US (2) US9975952B2 (pt)
EP (1) EP2943510B1 (pt)
JP (1) JP6382842B2 (pt)
KR (1) KR102155392B1 (pt)
CN (1) CN104968684B (pt)
AU (1) AU2014206130A1 (pt)
BR (1) BR112015016447A8 (pt)
CA (1) CA2896929C (pt)
CL (1) CL2015001939A1 (pt)
DK (1) DK2943510T3 (pt)
EA (1) EA031536B1 (pt)
ES (1) ES2674491T3 (pt)
HR (1) HRP20180917T1 (pt)
HU (1) HUE037843T2 (pt)
IL (1) IL239704B (pt)
IT (1) ITTO20130012A1 (pt)
LT (1) LT2943510T (pt)
ME (1) ME03080B (pt)
MX (1) MX360258B (pt)
PH (1) PH12015501539A1 (pt)
PL (1) PL2943510T3 (pt)
PT (1) PT2943510T (pt)
RS (1) RS57286B1 (pt)
SG (1) SG11201505114VA (pt)
SI (1) SI2943510T1 (pt)
TR (1) TR201808826T4 (pt)
WO (1) WO2014108829A1 (pt)
ZA (1) ZA201504748B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800003875A1 (it) * 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
KR102433184B1 (ko) * 2018-12-07 2022-08-17 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
CN113480645B (zh) * 2021-07-16 2022-11-11 甘肃中科博瑞生物工程有限公司 一种抗幽门螺旋杆菌重组抗体、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
PL1718677T3 (pl) 2003-12-19 2012-09-28 Genentech Inc Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
UA94213C2 (ru) * 2004-09-17 2011-04-26 Домантис Лимитед Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
SG169382A1 (en) * 2006-02-06 2011-03-30 Metheresis Translational Res S A Ch Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
CN103183738B (zh) * 2006-03-30 2014-08-06 诺瓦提斯公司 c-Met抗体的组合物和使用方法
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
ES2720136T3 (es) * 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Anticuerpo modificado con semivida mejorada
HUE039703T2 (hu) * 2011-08-23 2019-01-28 Roche Glycart Ag Bispecifikus antigénkötõ molekulák

Also Published As

Publication number Publication date
HRP20180917T1 (hr) 2018-08-10
RS57286B1 (sr) 2018-08-31
US20160017044A1 (en) 2016-01-21
MX360258B (es) 2018-10-26
ES2674491T3 (es) 2018-07-02
SG11201505114VA (en) 2015-07-30
HUE037843T2 (hu) 2018-09-28
US20180237527A1 (en) 2018-08-23
ITTO20130012A1 (it) 2014-07-10
PT2943510T (pt) 2018-07-02
JP2016503069A (ja) 2016-02-01
DK2943510T3 (en) 2018-07-02
KR20150103283A (ko) 2015-09-09
CN104968684B (zh) 2019-06-28
TR201808826T4 (tr) 2018-07-23
IL239704B (en) 2019-03-31
SI2943510T1 (en) 2018-08-31
ME03080B (me) 2019-01-20
EA201591279A1 (ru) 2015-11-30
LT2943510T (lt) 2018-07-10
WO2014108829A1 (en) 2014-07-17
CA2896929C (en) 2020-09-29
US9975952B2 (en) 2018-05-22
EA031536B1 (ru) 2019-01-31
KR102155392B1 (ko) 2020-09-11
AU2014206130A1 (en) 2015-07-30
US10351628B2 (en) 2019-07-16
CN104968684A (zh) 2015-10-07
CL2015001939A1 (es) 2016-04-01
JP6382842B2 (ja) 2018-08-29
EP2943510B1 (en) 2018-05-23
EP2943510A1 (en) 2015-11-18
CA2896929A1 (en) 2014-07-17
MX2015008779A (es) 2016-03-31
PH12015501539A1 (en) 2015-10-05
PL2943510T3 (pl) 2018-09-28
ZA201504748B (en) 2019-11-27
IL239704A0 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
EA201690314A1 (ru) Анти-garp-белок и его применения
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
CY1122478T1 (el) Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
BR112016020065A2 (pt) sítios específicos para modificar anticorpos para fazer imunoconjugados
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA202092435A2 (ru) Моноклональные антитела против bcma
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
BR112016024780A2 (pt) composições e métodos relacionados com construtos de fc manipulados
MD3273992T2 (ro) Anticorpi pentru ICOS
CY1122978T1 (el) Αντισωματα εναντι-vla-4
EA201591137A1 (ru) Ингибиторы mk2 и их применения
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
BR112018074032A2 (pt) composições e métodos relacionados a construtos de fc manipulados
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
EA201591465A1 (ru) Специфичные участки для модификации антител для получения иммуноконъюгатов
BR112015032224A2 (pt) anticorpos anti-fcrh5
EA201591962A1 (ru) Ингибиторы акк и их применение
UY34570A (es) Combinaciones de compuestos inhibidores de la proteína ns5a en el virus de hepatitis c

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2704 DE 01-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.